EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications

Kha Cong Le Bui iD, Yen Thi Do iD, Jin Young Kim iD, Ji Hae Seo iD

International Journal of Molecular Sciences · 29.05.2026 · 27 (11) · 4924

DOI: 10.3390/ijms27114924 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.05.2026. Verfasst von Kha Cong Le Bui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology B, Hue Central Hospital, Hue 49135, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Lipogenesis, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is increasingly recognized as a lipid-addicted malignancy in which de novo lipogenesis (DNL) supports tumor growth, survival, and treatment resistance. ccRCC-specific genetic alterations, particularly loss of VHL and activation of hypoxia-inducible factor (HIF) signaling, promote SREBP-mediated upregulation of key lipogenic enzymes, including ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD1). These pathways support membrane biogenesis and redox balance while also promoting metabolic flexibility, enabling adaptation to therapeutic and microenvironmental stresses. Emerging preclinical studies suggest that pharmacological inhibition of lipogenic enzymes, either alone or in combination with tyrosine kinase inhibitors, mTOR inhibitors, HIF-2α antagonists, or immune checkpoint blockade, may suppress ccRCC progression. However, most therapeutic data remain limited to preclinical models, and clinical validation is still lacking. This review synthesizes recent advances in molecular regulation and therapeutic targeting of DNL in ccRCC and discusses the challenges and future opportunities to improve mechanistic understanding and explore potential therapeutic applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellLipogenesisKidney NeoplasmsHumansAnimalsSignal TransductionMetabolic ReprogrammingATP Citrate (pro-S)-Lyase

Stichwörter der Autor:innen

VHL–HIF signalingclear cell renal cell carcinomade novo lipogenesislipid reprogramminglipogenesis inhibitorsmetabolic reprogramming

Substanzen

ATP Citrate (pro-S)-Lyase

Autor:innen und Institutionen

  • Department of Urology B, Hue Central Hospital, Hue 49135, Vietnam.
  • Division of Haematology and Oncology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
  • Department of Biochemistry, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.

ORCID-Profile: Kha Cong Le Bui, Yen Thi Do, Jin Young Kim, Ji Hae Seo

Förderung

  • National Research Foundation of Korea
  • Ministry of Science and ICT

Zitieren

APA

Bui, K. C. L., Do, Y. T., Kim, J. Y., & Seo, J. H. (2026). De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications. International Journal of Molecular Sciences, 27(11), 4924. https://doi.org/10.3390/ijms27114924

Vancouver

Bui KCL, Do YT, Kim JY, Seo JH. De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications. International Journal of Molecular Sciences. 2026;27(11):4924. doi:10.3390/ijms27114924

BibTeX
@article{Bui2026,
  author = {Bui, Kha Cong Le and Do, Yen Thi and Kim, Jin Young and Seo, Ji Hae},
  title = {De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {11},
  pages = {4924},
  doi = {10.3390/ijms27114924}
}
Kostenlos starten →